Monoclonal antibodies in multiple myeloma come of age

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1264-1266

  Raje, Noopur ^a   Longo, Dan L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARATUMUMAB; ELOTUZUMAB; ISATUXIMAB; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CD38 ANTIGEN;

CANCER INCIDENCE; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; EVENT FREE SURVIVAL; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; FEMALE; MALE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 84942437054     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1509419     Document Type: Editorial

References (10)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207-19.
3. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621-31.
4. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012; 26: 149-57.
5. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
6. Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011; 2011: 924058.
7. Maus MV, June CH. CARTs on the road for myeloma. Clin Cancer Res 2014; 20: 3899-901.
8. Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med 2015; 7: 288ra78.
9. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011; 117: 393-402.
10. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20: 4574-83.